Contrarian investors identify three beaten-down sectors with buying opportunities: financials (American Express, KKR, Apollo Global Management, Blue Owl Capital, Robinhood), healthcare (Molina Healthcare, Oscar Health, Hims Hers Health), and software (Microsoft, Oracle, ServiceNow, Figma). They recommend avoiding energy stocks, which have rallied too far on momentum and FOMO despite potential long-term gains.

Hims & Hers, Inc. discovered a data breach on February 5, 2026, affecting its computer network through a compromised Zendesk customer service platform. Between February 4-7, 2026, unauthorized users accessed customer service tickets containing personal information including names, contact details, and other sensitive data. Edelson Lechtzin LLP is investigating class action claims on behalf of affected individuals.

Novo Nordisk launched a subscription program for Wegovy (semaglutide) starting March 31, 2026, offering tiered pricing to reduce costs for self-pay patients. Monthly prices range from $329 to $249 for injections (up to $1,200 annual savings) and $289 to $249 for oral versions through telehealth partners including Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame expected to join later. The program aims to improve treatment adherence and address cost barriers.

Following the expiration of India's semaglutide patent, over 40 Indian pharmaceutical companies have launched generic versions of Novo Nordisk's Ozempic and Wegovy at dramatically reduced prices—approximately 70% cheaper than originals. Major players like Sun Pharmaceutical, Dr. Reddy's Laboratories, and Zydus Lifesciences are offering monthly treatments ranging from $7.99 to $44.73, with plans to expand into global markets including Canada, Brazil, and Latin America as the obesity market is projected to reach $100 billion by decade's end.

The FDA approved Wegovy HD (semaglutide) 7.2 mg, a higher-dose version of Novo Nordisk's weight-loss drug, for patients who have tolerated the standard 2.4 mg dose. The approval is based on the STEP UP clinical trial showing significant weight loss benefits. Wegovy HD will be available starting in April across 70,000+ U.S. pharmacies. Despite the approval, Novo Nordisk shares declined 2.05% at the time of publication.

The article identifies the top 10 most heavily shorted stocks as of March 11, 2026, with Lucid Group leading the list. It explains why stocks become heavily shorted, the mechanics of short squeezes, and notes that while high short interest can signal potential volatility and upside moves, timing such trades is challenging and investors should conduct thorough due diligence given the underlying business risks.

BLKBRD Asset Management fully liquidated its 318,666 shares of Hims & Hers Health (worth ~$18.07 million) in Q4 2025, representing a complete exit from a position that was 5.0% of the fund's AUM. The stock had plummeted 72.46% over the past year following Novo Nordisk's partnership termination and lawsuit. However, on March 10, 2026, Hims & Hers announced a new partnership with Novo Nordisk to offer weight-loss drugs Ozempic and Wegovy, causing the stock to surge 6% as the lawsuit was dropped.

European natural gas prices surged to three-year highs amid US-Israeli military operations against Iran, with the Dutch TTF rising 68% weekly due to supply disruption concerns. Europe remains politically divided on the strikes, with the UK, France, and Spain taking more cautious stances while Germany and Eastern Europe support US-Israeli actions. Weak industrial production data across the Euro Area and UK signals fragile economic growth, while energy price spikes threaten to accelerate inflation and complicate ECB policy decisions.

Hims & Hers stock surged 40% after announcing a deal with Novo Nordisk to sell Wegovy pills and Ozempic injections on its platform. The agreement resolves a major legal overhang from a February lawsuit and removes uncertainty around the companies' relationship. Despite the sharp price increase, the stock remains attractively valued at under 20x forward P/E, though investors should exercise caution given the volatile history between the two companies.

U.S. stock futures fell sharply on Monday as oil prices surged amid Iran-US conflict, with Brent Crude jumping 14.90% to $106.50 and WTI rising 13.27% to $102.96. Major indices declined with Dow Jones down 1.61%, S&P 500 down 1.41%, and Nasdaq 100 down 1.56%. Notable movers included Hims & Hers surging 49.36% after resolving disputes with Novo Nordisk, and UniQure gaining 35.88% following FDA clarity on its Huntington's disease therapy. Analysts warn of stagflationary pressures and systemic fragility in energy supply chains.

Hims & Hers Health and Novo Nordisk have resolved their legal dispute over patent violations and announced a partnership to sell weight-loss drugs through Hims & Hers' telehealth platform. While the company beat earnings expectations (8 cents vs. 3 cents estimated), Q1 and 2026 revenue guidance fell short of analyst estimates. HIMS shares surged 48.67% in premarket trading, though technical indicators show mixed signals with the stock trading well above its 20-day moving average but below its 100-day average.

Hims & Hers Health stock has declined 70% over the past year due to slowing GLP-1 drug sales after FDA ended shortage declarations and competitors cut prices. Q4 2025 earnings beat on profit but missed on sales, with quarterly growth halving to 28% from full-year 59%. However, management emphasizes that the majority of revenue comes from non-GLP-1 offerings and remains confident in achieving $2.8 billion in 2026 sales.